AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 283 min read$LH

Labcorp Holdings Inc. Q3 2026 Earnings Call Summary

Labcorp reported 7% revenue growth in Q3 2026, driven by diagnostics and biopharma. Enterprise margin expanded by 60 basis points. The company raised full-year guidance despite $10M in foreign currency headwinds. Management expects a $125M impact from PAMA in 2027. Recent acquisitions and the Launchpad initiative aim to offset reimbursement pressures. Biopharma growth is expected to be high-single-digit, supported by an $8.9B backlog.

Original reporting
finance.yahoo.com
Published Oct 28, 2026, 5:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 6:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Labcorp Holdings Inc. Q3 2026 Earnings Call Summary — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$LHNeutralMed
01

Why it matters

The guidance raise and acquisition announcements provide fresh material for investors, while reimbursement concerns introduce downside risk.

02

Market read

Labcorp's updated guidance and strategic acquisitions are likely to influence its stock and the broader lab services sector.

03

What to watch

Integration risk of multiple acquisitions and foreign currency headwinds may offset upside.

Relevance 8/10Novelty 8/10Timing: after earnings release today

Background

Labcorp's Q3 2026 earnings call covered revenue growth, margin expansion, new FDA‑cleared test, and several acquisitions.

Company-level read

Ticker impact

$LHNeutralHigh confidence
Context

Labcorp raised full-year 2026 guidance and disclosed multiple acquisitions, providing fresh earnings and strategic information.

Expected impact

likely modest upside as market prices in higher guidance, tempered by reimbursement pressure.

Evidence & confidence

New guidance numbers and acquisition details are primary disclosures that can move the stock in the near term.

Market effects

Sector

Positive for the diagnostics and central lab services sector as Labcorp's growth signals demand.

Regional

U.S. healthcare investors may adjust exposure to lab services.

Global

Limited; mainly affects U.S. biotech and pharma service providers.

Counterpoint

What could challenge this read

PAMA fee schedule could erode margins, making the guidance raise less sustainable.

Key entities

  • Company
    Labcorp Holdings Inc.

    U.S. diagnostics and central laboratory services provider.

  • Company
    MLM Medical Labs

    Acquired to create a wholly owned global network.

  • Company
    BioReference

    Asset acquisition contributing $260 M revenue.

  • Company
    Myriad Genetics

    Prenatal testing business acquisition.

Read at source← All news

StoryLabcorp posts Q3 2026 revenue and adjusted EPS growth and lifts full‑year guidance

Also covered by

5 outlets

Related articles

OCT 28
$LHHighAI 8/10

Labcorp (LH) Q3 2026 Earnings Call Transcript

LabCorp (LH) reported Q3 2026 revenue growth of 7% to $3.8B, EPS growth of 14.5% to $4.78, and raised 2026 guidance. The company expressed concerns over proposed PAMA fee schedule changes, which may reduce Medicare reimbursement rates. LabCorp highlighted growth in diagnostics and biopharma services, FDA approvals, and strategic acquisitions, including MLM Medical Labs and agreements with Myriad Genetics and Millennium Health.

finance.yahoo.com3 min
OCT 28
$LHHighAI 9/10

Labcorp (LH) stock trades up, here is why

Labcorp (LH) shares rose 10.3% after reporting Q3 revenue of $3.81B, beating estimates, and raising its full-year 2026 outlook to 5.9-6.7% revenue growth and $18.30-$18.70 adjusted EPS. The company's stock has gained 45.4% year-to-date, reaching a 52-week high of $365.79.

stockstory.org2 min
OCT 28
$LHHighAI 8/10

Labcorp Q3 Earnings Call Highlights

Labcorp reported Q3 revenue growth of 8.5% in biopharma services, with central lab services up 11.3%. Adjusted operating income rose to $159M. The company raised 2026 revenue and EPS guidance, citing strong organic performance. Labcorp also addressed PAMA-related reimbursement pressures expected in 2027 and announced several acquisitions.

finance.yahoo.com2 min
OCT 28
$WENMed

Stocks making the biggest moves midday: Wendy's, Wingstop, F5, Enphase Energy, Labcorp & more

Wendy's rose 15% on a $1.4B privatization proposal from Trian Fund. Brinker International and Wingstop gained 15% after raising guidance and beating earnings. F5 dropped 19% on weak guidance and a downgrade. Labcorp and GE HealthCare advanced on raised guidance. Ultralife surged 145% on a $320M acquisition deal. Enphase Energy fell 16% on missed revenue. PPG Industries rose 6% on earnings beat and raised guidance. Robinhood fell 2% on missed profit. SK hynix advanced 11% on strong earnings.

cnbc.com3 min